Biogen executives were forced to explain why their spinal muscular atrophy (SMA) drug Spinraza stopped in its tracks last quarter. After all, the launch had been speeding along till now. One thing's for sure, management promised: It's not because of Novartis' new rival therapy Zolgensma.
QUOTE
In the first quarter after Zolgensma’s debut, Spinraza posted a dip of 6%. Its $488 million in sales fell short of Street estimates by some $36 million, according to Piper Jaffray analysts. And that had market-watchers asking why.Seems spinraza sales are currently around $500 million per year and gradually declining due to competition but obviously that is not to be sniffed at.Don't blame the quarter-over-quarter decline on Novartis’ Zolgensma approval in May, Biogen execs stressed. The rival drug is only approved for patients 2 years old and younger, who represent only about 5% of the SMA market, they said.
https://www.fiercepharma.com/pharma/don-t-worry-about-zolgensma-biogen-execs-say-spinraza-has-room-to-grow
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.040(3.45%) |
Mkt cap ! $699.9M | |||
| Open | High | Low | Value | Volume |
| $1.19 | $1.20 | $1.18 | $97.44K | 81.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 19651 | 3 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |